Jupiter Asset Management Ltd. Raises Stock Holdings in Twist Bioscience Corporation $TWST

Jupiter Asset Management Ltd. increased its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 362.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 245,098 shares of the company’s stock after acquiring an additional 192,072 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Twist Bioscience were worth $6,897,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of TWST. Aberdeen Group plc raised its stake in shares of Twist Bioscience by 98.4% during the 3rd quarter. Aberdeen Group plc now owns 320,283 shares of the company’s stock worth $9,013,000 after purchasing an additional 158,879 shares during the period. Profund Advisors LLC increased its holdings in Twist Bioscience by 52.8% during the third quarter. Profund Advisors LLC now owns 24,654 shares of the company’s stock worth $694,000 after buying an additional 8,523 shares during the last quarter. Smartleaf Asset Management LLC raised its position in Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after acquiring an additional 442 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in Twist Bioscience by 90.4% in the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 265,851 shares of the company’s stock valued at $7,481,000 after acquiring an additional 126,260 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its position in shares of Twist Bioscience by 19.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 49,840 shares of the company’s stock valued at $1,402,000 after acquiring an additional 8,246 shares during the period.

Wall Street Analysts Forecast Growth

TWST has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, December 29th. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Stephens assumed coverage on Twist Bioscience in a research note on Monday, November 3rd. They issued an “overweight” rating and a $41.00 target price on the stock. Robert W. Baird set a $50.00 price target on Twist Bioscience in a research note on Tuesday, February 3rd. Finally, Evercore boosted their price objective on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $45.88.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CAO Robert F. Werner sold 7,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $45.65, for a total value of $319,550.00. Following the sale, the chief accounting officer directly owned 58,738 shares in the company, valued at $2,681,389.70. This represents a 10.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Adam Laponis sold 7,000 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $50.00, for a total transaction of $350,000.00. Following the completion of the transaction, the chief financial officer directly owned 130,031 shares of the company’s stock, valued at approximately $6,501,550. The trade was a 5.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 36,609 shares of company stock valued at $1,665,151. Company insiders own 3.08% of the company’s stock.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $48.59 on Friday. The firm has a market capitalization of $2.98 billion, a P/E ratio of -37.96 and a beta of 2.24. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $57.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37. The business has a fifty day moving average price of $40.59 and a 200-day moving average price of $33.15.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The company had revenue of $103.70 million for the quarter, compared to analysts’ expectations of $100.32 million. Twist Bioscience’s revenue for the quarter was up 16.9% on a year-over-year basis. As a group, equities research analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.